<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216371</url>
  </required_header>
  <id_info>
    <org_study_id>AN 20/04</org_study_id>
    <secondary_id>2008-007609-36</secondary_id>
    <nct_id>NCT01216371</nct_id>
  </id_info>
  <brief_title>Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)</brief_title>
  <acronym>SMAT</acronym>
  <official_title>Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association of Urologic Oncology (AUO)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association of Urologic Oncology (AUO)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim ist to identify biomarkers in the blood, to indicate early response or early
      treatment resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized multi-center Phase II trial for resection of metastases from pulmonary
      metastases (poor prognosis) in clear cell renal cell carcinoma + / - adjuvant sunitinib
      therapy over one year
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year relapse-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>perioperative mortality and morbidity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect of adjuvant therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life of the Patient</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Pulmonary Metastases</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one year adjuvant treatment with sunitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one year treatment with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break</description>
    <arm_group_label>Sunitinib</arm_group_label>
    <other_name>adjuvant Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Plazebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;/= 2 synchronous or within 24 Months after Nephrectomy occured pulmonary metastases.
             Patients in whom more back than 2 years of a solitary lung metastasis, bone metastasis
             or brain metastasis was resected, may also be included in the study.

          -  Aged 18 to 75 years

          -  functionally acceptable surgical risk

          -  Women in conceptional age: negative pregnancy test and adequate contraception

          -  Adequate hematologic, renal, hepatic and coagulation-physiological functions

          -  Amylase/ Lipase &lt; 1,5 x upper limit of normal

          -  Informing the patient about the study and the present written consent to participate
             after clarification in accordance with the stipulations of AMG(german drug law), and
             the principles of GCP (&quot;informed consent&quot;)

          -  Patient compliance and geographic proximity to allow adequate follow-up

        Exclusion Criteria:

          -  Presence of other metastases outside the lung

          -  progress in the 12-week sunitinib therapy before resection of metastases

          -  R1 or R2-finding in resection of metastases

          -  Dialysis after nephrectomy

          -  Previous or existing serious cardiovascular (grade III - IV according to NYHA(New York
             Heart Association)) disease, active angina pectoris or ischemia, myocardial infarction
             within previous 6 months , uncontrolled hypertension(RR diastolic 120 mmHg(Millimeters
             of mercury))

          -  serious hematopoetic (e.g. serious Bone marrow aplasia), pulmonary, hepatic or renal
             Disease

          -  Stroke within the previous six months

          -  Patients with poorly controlled diabetes mellitus

          -  Serious bacterial or fungal infections

          -  chronic hepatitis B or C, HIV(human immunodeficiency virus) infection

          -  autoimmune disease

          -  prior organ transplantation

          -  prior autologous bone marrow transplant or stem cell transferred within the last 4
             months before study

          -  Neuropsychiatric diseases that affect patient compliance

          -  Manifesto, second malignancy or other malignancy within the past 5 years (except basal
             cell carcinoma, carcinoma in situ of the cervix, incidental prostate carcinoma,
             superficial urothelial Ca pTaG1-2 and pT1G1)

          -  Therapy with immunotherapeutic agents including monoclonal antibodies, cytotoxic drugs
             or hormones (other than bisphosphonates and oral contraceptives) within the last 4
             weeks prior to enrollment. Previous use of inhibitors of Ras/Raf-, MEK kinase, AKT
             kinase and mTOR inhibitors or induction of Farnesyltransferase

          -  Previous use of angiogenesis inhibitors such as VEGF / VEGFR, PDGF / PDGFR and other
             key molecules of angiogenesis

          -  parallel treatment with rifampicin

          -  Participation in other treatment studies in the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Krege, Priv. Doz. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>urological hospital of Maria Hilf Krankenhaus Krefeld</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Krege, Priv. Doz. Dr. med.</last_name>
    <phone>02 151 / 334-23 81</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsmedizin Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steffen Weikert, Priv. Doz. Dr. med.</last_name>
      <phone>030/84 45-40 84</phone>
    </contact>
    <investigator>
      <last_name>Steffen Weikert, Priv. Doz. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kempkensteffen Carsten, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonas Busch, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Gregor, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Neudecker, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens C. Rückert, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gertrud Feldmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franziskus Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jörg Neymeyer, Dr. med.</last_name>
      <phone>030/26 38-38 01</phone>
    </contact>
    <investigator>
      <last_name>Jörg Neymeyer, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Wülfing, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Emil von Behring</name>
      <address>
        <city>Berlin</city>
        <zip>14165</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kollmeier Jens, Dr. med.</last_name>
      <phone>030/81 02-14 47</phone>
    </contact>
    <investigator>
      <last_name>Jens Kollmeier, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bettina Schlolaut, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>university hospital of Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40255</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Albers, Prof. Dr. med.</last_name>
      <phone>0211/811-81 10</phone>
    </contact>
    <investigator>
      <last_name>Peter Albers, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jasper Decoene</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zenginli Hakan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claus F. Eisenberger, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfram T. Knoefel, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Almut Diem</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>university hospital of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Rübben, Prof. Dr. med.</last_name>
      <phone>0201/723-32 10</phone>
    </contact>
    <investigator>
      <last_name>Herbert Rübben, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcus Schenk, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farnk vom Dorp, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Ju, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Tschirdewahn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela Löbert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik Department of Thoracic Surgery</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane Zimmermann</last_name>
      <phone>0201/433-43 24</phone>
    </contact>
    <investigator>
      <last_name>Georgios Stamatis, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Welter, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Fechner, Dipl. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>university hospital of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Wetterauer, Prof. Dr. med.</last_name>
      <phone>0761/270-2891</phone>
    </contact>
    <investigator>
      <last_name>Ulrich Wetterauer, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Leiber, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Stremmel, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jutta Günter, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>university Hospital of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69119</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Hohenfellner, Prof. Dr. med.</last_name>
      <phone>06221/56-63 21</phone>
    </contact>
    <investigator>
      <last_name>Markus Hohenfellner, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pahernick Sascha, Priv. Doz. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gencay Hatiboglu, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Huber, Dr. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joachim Pfannschmidt, Priv. Doz. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendrik Dienemann, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>urological hospital of Maria Hilf Krankenhaus Krefeld</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Krege, Priv. Doz. Dr. med.</last_name>
      <phone>02151/334-52 74</phone>
    </contact>
    <investigator>
      <last_name>Susanne Krege, Priv. Doz. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Hartmann, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Staehler, Dr. med.</last_name>
      <phone>089/70 95-0</phone>
    </contact>
    <investigator>
      <last_name>Michael Staehler, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cordula Nordhaus, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Nuhn, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hauke Winter, Priv. Doz. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rudolf Hatz, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvia Dondl</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr.-Horst-Schmidt-Kliniken GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Frickhofen, Prof. Dr. med.</last_name>
      <phone>0611/43-30 09</phone>
    </contact>
    <investigator>
      <last_name>Norbert Frickhofen, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernd Jung, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heinz G. Fuhr, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joachim Schirren, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Servet Bölükbas, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine Labenz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Birgit Wilde</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klaudia Fischbach</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>February 10, 2012</last_update_submitted>
  <last_update_submitted_qc>February 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association of Urologic Oncology (AUO)</investigator_affiliation>
    <investigator_full_name>Heidrun Rexer</investigator_full_name>
    <investigator_title>Priv. Doz. Dr. med. Susanne Krege, urological hospital of Maria Hilf Krankenhaus Krefeld</investigator_title>
  </responsible_party>
  <keyword>carcinoma</keyword>
  <keyword>metastases</keyword>
  <keyword>renal</keyword>
  <keyword>lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

